September is Blood Cancer Awareness Month. We stand with everyone living with blood cancer — this month and every day.

Publications & Presentations

Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.

Explore our scientific publications and presentations:

This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.

Journal articles

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Blood Neoplasia

April 16, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Blood Cancer Journal

April 7, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

British Journal of Haematology

February 1, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

January 22, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Nature Leukemia

January 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Blood Cancer Journal

December 31, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

Clinical and Translational Science

December 14, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Future Oncology

October 12, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims

Clinical Lymphoma, Myeloma and Leukemia

October 1, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of Patients With Lower-Risk Myelodysplastic Syndromes and Anemia

Online First

June 25, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Review

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis

Clinical and Translational Science

January 21, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science

Clinical and Translational Science

November 21, 2024
Review

Conference presentations

Favorable Overall Survival of Imetelstat-treated Relapsed/Refractory Myelofibrosis Patients Compared with Closely Matched Real World Data

EHA 2019

June 12, 2019
Myelofibrosis (MF)Clinical Data

Imetelstat Treatment Leads to Durable Transfusion Independence in RBC Transfusion-Dependent, Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent Who Are Lenalidomide and HMA Naive

ASH 2018

December 5, 2018
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

ASH 2018

December 5, 2018
Myelofibrosis (MF)Clinical Data

Imetelstat in RBC Transfusion-Dependent Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (IMerge): Updated Efficacy and Safety

EHA 2018

June 12, 2018
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

ASH 2017

December 5, 2017
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

ASH 2017

December 5, 2017
Myelofibrosis (MF)Preclinical Data

Telomerase Inhibition Impairs Self-Renewal of b-Catenin Activated Myeloproliferative Neoplasm Progenitors

ASH 2017

December 5, 2017
Preclinical Data

Integrated Molecular Analysis Identifies Replicative Stress as Sensitizer to Imetelstat Therapy in AML

ASH 2017

December 5, 2017
Acute Myeloid Leukemia (AML)Preclinical Data

Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia

AACR 2017

April 15, 2017
Acute Myeloid Leukemia (AML)Preclinical Data

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts

ASH 2016

December 5, 2016
Acute Myeloid Leukemia (AML)Preclinical Data

Telomerase Inhibition with Imetelstat Eradicates β-catenin Activated BC CML Stem Cells

ASH 2016

December 5, 2016
Preclinical Data

Characterization of Disease, Treatment Patterns, and Outcomes of Patients With Myelofibrosis: Analysis of Two United States Commercial Claims Databases

ASH 2016

December 5, 2016
Myelofibrosis (MF)